Calidi Biotherapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Calidi Biotherapeutics, Inc. (CLDI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 87.20% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-06-30 was 87.20%, a 0.00% change year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 88.50%, a 2.60% increase year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 87.20%.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 86.90%, a 1.85% decline year-over-year.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 87.84%, a 2.58% increase from fiscal 2024.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 85.63%, a 3.53% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 88.76%, a 0.46% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 88.35%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 87.20% 10-Q · filed 2026-08-13 | 87.20% 10-Q · filed 2026-08-13 | ||
| 2025-12-31 | 87.84% 10-K · filed 2026-03-27 | |||
| 2025-09-30 | 88.50% 10-Q · filed 2025-11-13 | 87.84% 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 87.20% 10-Q · filed 2026-08-13 | 87.00% 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | 86.90% 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 85.63% 10-K · filed 2026-03-27 | |||
| 2024-09-30 | 86.26% 10-Q · filed 2025-11-13 | 85.62% 10-Q · filed 2025-11-13 | ||
| 2024-03-31 | 88.54% 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 88.76% 10-K · filed 2025-03-31 | |||
| 2023-09-30 | 84.97% 10-Q · filed 2024-11-12 | 89.23% 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 87.81% 10-Q · filed 2024-08-13 | 89.34% 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | 89.80% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 88.35% 10-K · filed 2024-03-15 | |||
| 2022-09-30 | 88.13% 10-Q · filed 2023-11-14 | 88.40% 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |